Fusobacterium necrophorum subsp. necrophorum Liver Abscess with Pylephlebitis: An Abdominal Variant of Lemierre’s Syndrome

Table 2

Summary of the patient demographics, underlying comorbidities, clinical features, treatment, and outcomes of all previously published case reports of patients with septic portal vein thrombosis secondary to Fusobacterium necrophorum.

Case

Reference (year)

Country

Age

Sex

Primary source of infection

CIR

CA

ALC

ABP

HCD

Fever

Leukocytosis

BCT

ASC

AST

ALT

ALP

Additional thrombosis

ABX (duration in weeks)

AC (duration in months)

Outcome

1.

Soo (1999)

Australia

31

M

GI tract (presumed)

No

NR

NR

Yes

No

Yes

Yes

Yes

No

79

133

295

SMV

CIP + MET (1) Augmentin (6)

Warfarin (6)

Full recovery

2.

Clarke (2003)

UK

19

F

GYN procedure or sore throat

No

NR

NR

Yes

n/a

Yes

Yes

Yes

Yes

NR

52

331

SMV

Abscess drainage CIP + MET + PCN (6.5)

Warfarin (long term)

Residual pH

3.

Redford (2005)

UK

53

M

NI

No

No

Yes

Yes

NR

Yes

Yes

Yes

NR

75

38

194

No

PCN + MET (2) CLINDA PO (5)

Warfarin (3)

Full recovery

4.

Shahani (2011)

USA

34

M

Pancreatitis liver abscess

No

NR

Yes

Yes

No

No

Yes

No

Yes

WNL

WNL

WNL

SMV + SV

VANC + MET + TIG (4)

No

Improved

5.

DePetrillo (2014)

USA

53

M

NI

No

NR

Yes

Yes

NR

Yes

Yes

Yes

NR

NR

70

152

No

Ertapenem (4)

Warfarin

Improved

6.

Akhrass (2015)

USA

32

M

Appendicitis

No

n/a

No

Yes

No

Yes

Yes

Yes

NR

WNL

WNL

WNL

SMV + SV

VANC + PIP-TAZ + MET + CLIND PO

THET + warfarin (6)

Full recovery

7.

Radovanovic (2018), current case

USA

69

M

NI oral cavity (presumed)

No

Tongue SCC

Yes

Yes

No

Yes

Yes

Yes

Yes

39

68

518

HV

Abscess drainage + CEFT + MET (3) + augmentin (2)

Warfarin (3)

Clinically improved (lost in follow-up)

ABP, abdominal pain; ABX, antibiotics; AC, anticoagulation; ALK, alcoholism; ASC, cultures from aspirate from intra-abdominal infection; BCT, blood cultures; CIR, cirrhosis; CIP, ciprofloxacin; CLINDA, clindamycin; F, female; GI, gastrointestinal; GYN, gynecological; HCD, hypercoagulable disorder; HV, hepatic vein; M, male; MET, metronidazole; NI, not identified; NR, not reported; PCN, penicillin; PH, portal hypertension; PIP-TAZ, piperacillin-tazobactam; PO, oral; SC, splenic vein; SVT, superior mesenteric vein; TIG, tigecycline; THET, trans-hepatic endovascular thrombolysis; UK, United Kingdom; USA, United States of America; VANC, vancomycin; WNL, within normal limits.